OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Basel-A series of product approvals in recent weeks could go some way to compensate for setbacks in Novartis’ pipeline. The approvals came as the Swiss company reported healthy half-year figures and an 11 percent sales increase.